Statement: Every adverse event in the primary trial occurred once.
Primary_evidence: Adverse Events 1:   Total: 7/45 (15.56%)   Febrile neutropenia 1/45 (2.22%)   Cardiac ischemia/infarction 1/45 (2.22%)   Ventricular arrhythmia - left ventricular systolic dysfunction 1/45 (2.22%)   Hemmorhage - GI 1/45 (2.22%)   Pancreatitis 1/45 (2.22%)   Infection - pneumonia 1/45 (2.22%)   Infection - Streptococcus 1/45 (2.22%)   Abcess of Bartholin's cyst 1/45 (2.22%)